Silexion Therapeutics (SLXN) Cash from Operations (2023 - 2026)
Silexion Therapeutics (SLXN) posted quarterly Cash from Operations of 3646000.0 for Q1 2026, down 48.63% year-over-year from 7098125.4 in Q1 2025, and down 20.89% quarter-over-quarter from 3016000.0 in Q4 2025.
Silexion Therapeutics (SLXN) Cash from Operations (2023 - 2026) Analysis & Trends
Silexion Therapeutics' Cash from Operations history runs 4 years deep, the most recent figure standing at 3646000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 48.63% year-over-year to 3646000.0; the TTM figure through Mar 2026 stood at 12012000.0 (down 32.04% YoY), while the FY2025 annual figure was 10819000.0, down 28.86% from the prior year.
- Cash from Operations for Q1 2026 stood at 3646000.0, down from 3016000.0 in the prior quarter.
- The five-year high for Cash from Operations was 685000.0 in Q3 2023, with the low at 3646000.0 in Q1 2026.
- The 4-year median for Cash from Operations is 2480000.0 (2025), against an average of 2206583.33.
- Peak annual rise in Cash from Operations reached 36.46% in 2024, while the deepest fall reached 287.3% in 2024.
- Silexion Therapeutics' Cash from Operations stood at 1257000.0 in 2023, then plunged by 132.78% to 2926000.0 in 2024, then slipped by 3.08% to 3016000.0 in 2025, then declined by 20.89% to 3646000.0 in 2026.
- Business Quant data shows SLXN's Cash from Operations at 3646000.0 in Q1 2026, 3016000.0 in Q4 2025, and 2843000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Silexion Therapeutics | 266,692.97 | -1.96 Mn | - | -2.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.93 Mn |
| Jun 30, 2026 | -2.93 Mn |
| Mar 31, 2026 | -3.65 Mn |
| Mar 31, 2026 | -3.65 Mn |
| Dec 31, 2025 | -3.02 Mn |
| Dec 31, 2025 | -3.02 Mn |
| Sep 30, 2025 | -2.84 Mn |
| Sep 30, 2025 | -2.84 Mn |
| Jun 30, 2025 | -2.51 Mn |
| Jun 30, 2025 | -2.51 Mn |
| Mar 31, 2025 | -2.45 Mn |
| Mar 31, 2025 | -2.45 Mn |
| Dec 31, 2024 | -2.93 Mn |
| Dec 31, 2024 | -2.93 Mn |
| Sep 30, 2024 | -2.65 Mn |
| Sep 30, 2024 | -2.65 Mn |
| Jun 30, 2024 | -1.07 Mn |
| Jun 30, 2024 | -1.07 Mn |
| Mar 31, 2024 | -1.75 Mn |
| Mar 31, 2024 | -1.75 Mn |